All News

Herpes Zoster and Rheumatoid Arthritis: Dr. Akhil Sood ( @AkhilSoodMD) reviews abstract #0981 presented at the #ACR21 annual meeting. https://t.co/M95XQOBWVf https://t.co/X9vaAEAias

Links:

Dr. John Cush RheumNow ( View Tweet)
GLORIA Study - Is Prednisone Harmful in Elder RA? The GLORIA study (ABST#1678) was a pragmatic, blinded placebo-controlled randomized trial where they assessed whether prednisolone (vs. placebo) use would alter clinical outcomes over 2 years. https://t.co/eKXjiDpHlc https://t.co/JtCgc1uZnE

Links:

Dr. John Cush RheumNow ( View Tweet)
Conway still

GLORIA Study - Is Prednisone Harmful in Elder RA?

d Jack Cush, MD

The GLORIA study (ABST# 1678) was a pragmatic, blinded placebo-controlled randomized trial from Dr. Martin Boers and colleagues where they assessed whether prednisolone (vs. placebo) use would alter clinical outcomes over 2 years.

Read Article
Potpourri of Biosimilar Trials: Dr. Jonathan Kay discusses a number of biosimilar trials presented at the #ACR21 annual meeting, including abstracts #0822, #0820, #0817 and #0823. https://t.co/aQXrKKZXhb https://t.co/4Bn7rvogHY

Links:

Dr. John Cush RheumNow ( View Tweet)
Lipidomic Differences in PsA and RA: Dr. Pedro Castillo ( @_Castillo_Pedro) discusses abstract #0946 presented at the #ACR21 annual meeting. https://t.co/M8O1OdvFAk https://t.co/4QMgXPhLzn

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

d Jack Cush, MD

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
heel enthesitis spur calcaneal

Predicting RA, and Treatment of Subclinical Arthritis

d Meral K. El Ramahi, MD, FACP, FACR

Identifying patients that will develop RA in situations of seropositivity without overt clinical arthritis or identifying patients with undifferentiated oligo/polyarthritis that will develop RA remains a challenge in the field of rheumatology. 

Read Article
Can "Ultra-low" dose Rituximab work for RA? At day 3 of #ACR21, the REDO trial presented data in abs1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid arthritis. Dr. Eric Dein ( @ejdein1) shares highlights. https://t.co/jaTjBPRKVe https://t.co/7Q9nxlUt7R

Links:

Dr. John Cush RheumNow ( View Tweet)
RA: Cardiovascular Risk Stratification and Potential Predictors of Risk Dr. El Ramahi ( @MeralElRamahiMD ) shares important takeaways from abstracts presented at #ACR21. https://t.co/69E7aA0Wag https://t.co/6nR5TLeyga

Links:

Dr. John Cush RheumNow ( View Tweet)
Cognitive Impairment in Patients with Rheumatoid Arthritis Dr. Akhil Sood ( @AkhilSoodMD) discusses abstracts presented at #ACR21. https://t.co/zz8auqZjIW https://t.co/RSHjyonBrj

Links:

Dr. John Cush RheumNow ( View Tweet)
iv.infusion.jpg

Can "Ultra-low" dose Rituximab work for RA?

d Eric Dein, MD

The REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid arthritis. Their study randomized 118 patients with rheumatoid arthritis to 1000 mg, 500 mg, and "ultra-low" dose 200 mg.

Read Article
heart2.ekg_.red_.jpg

RA: Cardiovascular Risk Stratification and Potential Predictors of Risk

d Meral K. El Ramahi, MD, FACP, FACR

Early cardiovascular disease assessment and management is critical at diagnosis in patients with Rheumatoid Arthritis (RA).

Read Article
Can we Use Frax Score in RA Patients? Dr. Eric Dein ( @ejdein1) reviews abstract #0563 presented at the #ACR21 annual meeting. https://t.co/UcvTWhlcvW https://t.co/8AdHa2enlz

Links:

Dr. John Cush RheumNow ( View Tweet)
brain.mri2_.jpg

Cognitive Impairment in Patients with Rheumatoid Arthritis

d Akhil Sood, MD

Evidence suggests that RA patients are at increased risk for cognitive impairment. This is likely mediated by certain factors, including chronic inflammation and accelerated atherosclerosis. In the clinical setting, it is important to identify RA patients at increased risk for cognitive impairment.

Read Article
switch.jpg

Monitoring Infliximab Drug Levels Improves Efficacy

d Robert Chao, MD

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?

Read Article
Abst 1515 Williams & colleagues studied role of CD4+ and CD8+ PD-1+ T cells in patients with early RA - CD4+ and CD8+ T PD-1+ T cells were dominant cell types in synovial tissue - 6 months after treatment, gene expression of CD4+ PD-1+ T cells decreased #ACR21 @RheumNow https://t.co/TWLym8oHuK
Akhil Sood MD AkhilSoodMD ( View Tweet)
Put those two RF together (essentially nailing down RA pts at risk of cancer): age >65 or ever smoked, all tofa vs TNFi: HR 1.55 (1.05-2.30) age >65 or ever smoked, tofa 5 bid vs TNFi: HR 1.44 (0.93-2.24) neither RF, all tofa vs TNFi: HR 1.16 (0.53-2.55) #ACR21 @RheumNow https://t.co/Uvr4wBhFVF
David Liew drdavidliew ( View Tweet)
#ACR21 Ab#1941: ORAL Surveillance VTE risk ▶️Tofa 10 BID risk > 5 BID > TNFi for VTE, DVT, PE ▶️Age, male, obesity, HTN, h/o VTE, oral contraception/HRT, steroids, antidepressants were risk factors @RheumNow https://t.co/JOKNyYVZfX https://t.co/mTkgkwPIT6

Links:

Eric Dein ericdeinmd ( View Tweet)
Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA>PsA>AS>PsO . HRs 1.1-1.6 compared to general population. Abstr#1925 #ACR21 @RheumNow https://t.co/kKlGQM5Tcg
Richard Conway RichardPAConway ( View Tweet)
#ACR21 Ab#1939: Tofa CV Outcome (STAR-RA) ▶️Pooled data does not show ⬆️ risk of CVD ▶️Trend in pts w prior CVD -HR 1.27 (0.95-1.7), cannot r/o CVD risk in pts w risk factors Less clear than oral surveillance data, but concerns in those w risks https://t.co/JOKNyYVZfX @Rheumnow https://t.co/GGYJfxcqhc

Links:

Eric Dein ericdeinmd ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.